Trillium Therapeutics (TSX:TRIL)(NASDAQ:TRIL) is a Mississauga-based clinical stage immuno-oncology company. Its stock has soared more than 1,500% over the past three months as of close on January 27.
Shares have been incredibly volatile over the past decade, richly rewarding investors who entered at the right now and harshly punishing those who have jumped in at its highs.
In January, the company announced that it had regained compliance with the NASDAQ Capital Market minimum bid price requirement. It is now dual listed once again.
Trillium started to gain significant momentum after the release of its third quarter 2019 results in November 2019. It announced that it planned to refocus its clinical development efforts on the intravenous administration of TTI-621, its anti-CD47 product.
This year, Trillium provided an enthusiastic update on its TTI-621 and TTI-622 programs. The phase 1 study of intravenous TTI-621 was particularly promising.
According to a recent report from Coherent Market Insights, the global immuno-oncology drugs market is expected to surpass $172.7 billion U.S. by 2026. This would represent a compound annual growth rate (CAGR) of 14.9% from the forecast period stretching from 2018 to 2026.
Biotech has remained one of the highest growth markets for investors over the past decade.
This company has shown promise, but its product candidates are still in very early stages. Investors should exercise caution and consider this a speculative buy in early 2020.
